Chronic Hepatitis C in Pregnant Persons: What You Need to Know About Treatment

Clinical Scenario

This protocol addresses chronic hepatitis C infection in pregnant persons — a situation where treatment decisions require individualised evaluation rather than a standard approach.

Why Pregnancy Is the Central Factor

Pregnancy fundamentally shapes management of chronic hepatitis C. Treatment may be considered, but only after a careful, case-by-case discussion of potential risks and benefits unique to both the pregnant person and the pregnancy itself.

Treatment Approach — Partial Overview

A direct-acting antiviral (DAA) strategy is within scope for consideration — but whether and how it applies in a given pregnancy is not straightforward. The full protocol details the framework and conditions under which this is evaluated.

Treatment goal: SVR12 — undetectable HCV RNA at 12 weeks post-therapy

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciad319

The Guidance Panel suggests that DAA treatment may be considered during pregnancy on a case-by-case basis after a discussion of potential risks and benefits.

SVR12, sustained virologic response 12 weeks after completion of therapy.

View source ↗